A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

Clinical trial NCT07602582 · RECRUITING

Trial details

NCT number: NCT07602582
Sponsor: Eli Lilly and Company
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Alzheimer Disease Dementia Plaque, Amyloid

Start date: 2026-05-22
Primary completion: 2029-09-01
Enrollment: 550

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.